Could a daily probiotic help protect aging brains?
NCT ID NCT06670807
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether a probiotic supplement taken daily for 16 weeks can improve cognitive function in older adults with mild cognitive impairment (MCI), a condition that raises the risk of dementia. One hundred participants aged 60 to 85 will be randomly assigned to receive either the probiotic or a placebo. Researchers will measure changes in brain activity, memory tests, and gut bacteria to see if the supplement offers any benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a probiotic dietary supplement called AB-MIND+CECT7481
- What this could lead to
- If it works, this could point toward a simple, safe way to slow or reverse early memory decline and reduce dementia risk.
- What could go wrong
- This is a small, early-stage trial with only 100 participants, and the effect on cognition may be modest or absent. Probiotics are generally safe but individual results can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women aged between 60 and 85 years. * Present "Mild Cognitive Impairment" (MCI) based on: * MoCA test (\< 26 points) or score adjusted for educational level * and CDR test (≤ 0.5 points) * Maintain functional capacity according to the (I)ADL test (≥ 70 points) * Show "cognitive concern" reported by the participant and/or a surrogate caregiver * Demonstrate longitudinal decline in cognitive function (progressive and not stabilized) for more than 3-5 years. * BMI ≥ 20 and \< 30 kg/m² * Absence of a family or social environment that prevents treatment adherence. * Adequate cultural level and understanding of the clinical study. * Agree to participate voluntarily in the study and provide written informed consent. Exclusion Criteria: * Subjects with severe neurological or psychiatric disorders due to any of the following causes: severe dementia, depression, epilepsy, schizophrenia, or bipolar disorder. * Subjects who have suffered a severe stroke prior to the study (FAZKAS=3) * Subjects with a history of malignancy \< 5 years (\< 5 years if the brain was affected) * Subjects who have experienced severe traumatic brain injury with structural brain injury and/or prior brain surgery * Subjects with pacemakers and those with metal implants that may interfere with EEG or MRI * Subjects treated with medications: benzodiazepines, neuroleptics, narcotics, anticonvulsants, or sedative-hypnotics in the last 3 months * Subjects who have been treated with antibiotics or probiotic supplements at least 3 months before the start of the study. * Subjects with hearing or visual impairments that prevent the evaluations included in the study * Subjects with severe illnesses affecting nutritional status (liver, kidney, etc.) * Subjects who have engaged in weight loss diets or significant dietary changes in the 8 weeks prior to starting the study * Subjects with high alcohol consumption (\> 3 alcoholic beverages per day)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mild cognitive impairment (MCI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Facultad de Farmacia Universidad Complutense de Madrid (UCM) Plaza Ramón y Cajal
NOT_YET_RECRUITINGMadrid, Madrid, 28040, Spain
-
Hospital Clínico San Carlos
RECRUITINGMadrid, Madrid, 28040, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A brain zapping and tai chi combo may slow memory decline
- Can a dead probiotic revive aging brains?
- Could a breath test reveal Parkinson's risk?
- A new web tool aims to ease tough tech decisions for dementia families
- A smart wearable could detect dementia early — before symptoms worsen
- Can Brain-and-Body drills slow memory decline?